featured
CV Biomarker Changes With Ertugliflozin in CKD and T2D
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Diabetes Care
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes
Diabetes Care 2021 Jan 12;[EPub Ahead of Print], PR Lawler, H Liu, C Frankfurter, LE Lovblom, Y Lytvyn, D Burger, KD Burns, D Brinc, DZI CherneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.